UCB’s Cimzia Could Be Delayed Until 2008 Or Later For Crohn’s
This article was originally published in The Pink Sheet Daily
A key regulatory concern for the biologic is a lack of induction evaluation criteria in one of two pivotal Crohn’s trials, the firm tells “The Pink Sheet” DAILY.
You may also be interested in...
Exec discusses the anti-TNF market and the entry of Abbott’s Humira – the first competitor for Remicade – in Crohn’s disease.
Abbott’s adalimumab will compete with Johnson & Johnson’s Remicade in the Crohn’s market following approval of an sBLA for the indication.
Firm says FDA seeks new information and clarification regarding the BLA.